A Single Center, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Fremanezumab (675 mg Quarterly) in Female Patients Aged 18-45 With Menstrual Migraine
Latest Information Update: 21 May 2024
At a glance
- Drugs Fremanezumab (Primary)
- Indications Menstrual migraine
- Focus Therapeutic Use
Most Recent Events
- 14 May 2024 Planned End Date changed from 1 Jul 2026 to 30 Jul 2026.
- 14 May 2024 Status changed from not yet recruiting to recruiting.
- 20 Dec 2023 New trial record